NASDAQ:BCRX BioCryst Pharmaceuticals (BCRX) Stock Price, News & Analysis → The new financial threat that could wipe out millions… (From InvestorPlace) (Ad) Free BCRX Stock Alerts $5.10 -0.16 (-3.04%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$5.04▼$5.4250-Day Range$4.13▼$5.7152-Week Range$4.03▼$8.96Volume3.79 million shsAverage Volume3.39 million shsMarket Capitalization$1.05 billionP/E RatioN/ADividend YieldN/APrice Target$14.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get BioCryst Pharmaceuticals alerts: Email Address BioCryst Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside171.8% Upside$14.00 Price TargetShort InterestBearish16.67% of Shares Sold ShortDividend StrengthN/ASustainability-1.85Upright™ Environmental ScoreNews Sentiment0.57Based on 40 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.69) to ($0.26) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.81 out of 5 starsMedical Sector215th out of 905 stocksBiological Products, Except Diagnostic Industry26th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingBioCryst Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBioCryst Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about BioCryst Pharmaceuticals' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted16.67% of the outstanding shares of BioCryst Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverBioCryst Pharmaceuticals has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.Change versus previous monthShort interest in BioCryst Pharmaceuticals has recently increased by 6.64%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioCryst Pharmaceuticals does not currently pay a dividend.Dividend GrowthBioCryst Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBioCryst Pharmaceuticals has received a 60.25% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Influenza medication", "Clinical research services for physical health", and "Hereditary angioedema medicine" products. See details.Environmental SustainabilityThe Environmental Impact score for BioCryst Pharmaceuticals is -1.85. Previous Next 3.7 News and Social Media Coverage News SentimentBioCryst Pharmaceuticals has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 40 news articles for BioCryst Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest12 people have searched for BCRX on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows8 people have added BioCryst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioCryst Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.40% of the stock of BioCryst Pharmaceuticals is held by insiders.Percentage Held by Institutions85.88% of the stock of BioCryst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioCryst Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioCryst Pharmaceuticals are expected to grow in the coming year, from ($0.69) to ($0.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioCryst Pharmaceuticals is -4.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioCryst Pharmaceuticals is -4.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about BioCryst Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCould this Tiny Biotech End Disease Forever?Imagine a revolutionary treatment capable of editing out ANY disease. By literally "cutting" the genetic instructions that cause illness, and "pasting" in corrected DNA to restore perfect health.Access my full "Cut & Paste" profit analysis now. About BioCryst Pharmaceuticals Stock (NASDAQ:BCRX)BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Read More BCRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCRX Stock News HeadlinesMay 8, 2024 | americanbankingnews.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target Increased to $15.00 by Analysts at JMP SecuritiesMay 8, 2024 | americanbankingnews.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Given "Buy" Rating at Needham & Company LLCMay 8, 2024 | InvestorPlace (Ad)The new financial threat that could wipe out millions…During the Internet boom, companies like Pets.com were supposed to be promising investments riding the wave of a new tech boom. But then they were gone within a blink of an eye. One of the most successful investors in history just stepped forward to say the same thing is about to happen to AI stocks.May 8, 2024 | americanbankingnews.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Receives "Buy" Rating from HC WainwrightMay 8, 2024 | americanbankingnews.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 5.5% Following Earnings BeatMay 7, 2024 | markets.businessinsider.comBuy Rating for BioCryst’s Orladeyo: Poised for Pediatric Market Growth and Continued HAE Market PenetrationMay 7, 2024 | bizjournals.comWhy this RTP public company expects big revenue gains in 2024May 7, 2024 | finance.yahoo.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2024 Earnings Call TranscriptMay 8, 2024 | InvestorPlace (Ad)The new financial threat that could wipe out millions…During the Internet boom, companies like Pets.com were supposed to be promising investments riding the wave of a new tech boom. But then they were gone within a blink of an eye. One of the most successful investors in history just stepped forward to say the same thing is about to happen to AI stocks.May 7, 2024 | finance.yahoo.comBioCryst Pharmaceuticals Inc (BCRX) Q1 2024 Earnings Call Transcript Highlights: Key Financial ...May 7, 2024 | globenewswire.comBioCryst to Present at Upcoming Investor ConferencesMay 7, 2024 | seekingalpha.comBioCryst: Estimate-Beating Q1 But Risks Are ConsiderableMay 7, 2024 | finance.yahoo.comQ1 2024 BioCryst Pharmaceuticals Inc Earnings CallMay 7, 2024 | americanbankingnews.comStock Traders Purchase Large Volume of BioCryst Pharmaceuticals Call Options (NASDAQ:BCRX)May 6, 2024 | fool.comWhy BioCryst Pharmaceuticals Vaulted Nearly 20% Higher on MondayMay 6, 2024 | marketwatch.comBioCryst Pharma Shares Jump on Strong 1QMay 6, 2024 | msn.comBioCryst Pharmaceuticals 'Fantastic' Q1 Earnings Rides On Outstanding Orladeyo PerformanceMay 6, 2024 | markets.businessinsider.comBioCryst Pharmaceuticals Reports Q1 Loss, Tops Revenue EstimatesMay 6, 2024 | fool.comBioCryst Pharmaceuticals (BCRX) Q1 2024 Earnings Call TranscriptMay 6, 2024 | finanznachrichten.deBioCryst Pharmaceuticals, Inc.: BioCryst Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 6, 2024 | finance.yahoo.comBioCryst Pharmaceuticals Reports Strong Q1 2024 Results, Exceeding Analyst Revenue ForecastsMay 6, 2024 | seekingalpha.comBioCryst Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 6, 2024 | seekingalpha.comBioCryst Pharmaceuticals beats top-line and bottom-line estimates; updates FY24 outlookMay 6, 2024 | globenewswire.comBioCryst Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 4, 2024 | americanbankingnews.comBioCryst Pharmaceuticals (BCRX) Scheduled to Post Earnings on MondayMay 3, 2024 | finanznachrichten.deBioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 3, 2024 | globenewswire.comBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)See More Headlines Receive BCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioCryst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2024Today5/08/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:BCRX CUSIP09058V10 CIK882796 Webwww.biocryst.com Phone(919) 859-1302Fax919-859-1314Employees536Year Founded1986Price Target and Rating Average Stock Price Target$14.00 High Stock Price Target$30.00 Low Stock Price Target$10.00 Potential Upside/Downside+174.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-226,540,000.00 Net Margins-68.36% Pretax Margin-68.26% Return on EquityN/A Return on Assets-36.96% Debt Debt-to-Equity RatioN/A Current Ratio3.31 Quick Ratio3.12 Sales & Book Value Annual Sales$331.41 million Price / Sales3.18 Cash FlowN/A Price / Cash FlowN/A Book Value($2.22) per share Price / Book-2.30Miscellaneous Outstanding Shares206,330,000Free Float197,252,000Market Cap$1.05 billion OptionableOptionable Beta1.96 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Jon P. Stonehouse (Age 63)CEO, President & Executive Director Comp: $1.23MMr. Anthony J. Doyle (Age 44)Senior VP, CFO & Treasurer Comp: $845.93kMs. Alane P. Barnes (Age 58)Senior VP, Chief Legal Officer & Corporate Secretary Comp: $794.75kMs. Jinky Ang RosselliChief Data & Insights OfficerMr. Philip GeorgeChief Strategy OfficerMr. Clayton FletcherChief Business Development OfficerMore ExecutivesKey CompetitorsNantKwestNASDAQ:NKNovavaxNASDAQ:NVAXAutolus TherapeuticsNASDAQ:AUTLScholar RockNASDAQ:SRRKMesoblastNASDAQ:MESOView All CompetitorsInsiders & InstitutionsInspire Investing LLCBought 6,141 shares on 5/8/2024Ownership: 0.034%Russell Investments Group Ltd.Bought 39,205 shares on 5/8/2024Ownership: 0.028%ProShare Advisors LLCBought 4,041 shares on 5/8/2024Ownership: 0.024%Swiss National BankSold 9,500 shares on 5/7/2024Ownership: 0.176%SG Americas Securities LLCSold 52,675 shares on 5/7/2024Ownership: 0.007%View All Insider TransactionsView All Institutional Transactions BCRX Stock Analysis - Frequently Asked Questions Should I buy or sell BioCryst Pharmaceuticals stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BCRX shares. View BCRX analyst ratings or view top-rated stocks. What is BioCryst Pharmaceuticals' stock price target for 2024? 7 brokers have issued 12-month target prices for BioCryst Pharmaceuticals' shares. Their BCRX share price targets range from $10.00 to $30.00. On average, they expect the company's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 171.8% from the stock's current price. View analysts price targets for BCRX or view top-rated stocks among Wall Street analysts. How have BCRX shares performed in 2024? BioCryst Pharmaceuticals' stock was trading at $5.99 at the beginning of 2024. Since then, BCRX shares have decreased by 14.0% and is now trading at $5.15. View the best growth stocks for 2024 here. Are investors shorting BioCryst Pharmaceuticals? BioCryst Pharmaceuticals saw a increase in short interest in April. As of April 15th, there was short interest totaling 34,390,000 shares, an increase of 6.6% from the March 31st total of 32,250,000 shares. Based on an average trading volume of 3,130,000 shares, the short-interest ratio is currently 11.0 days. View BioCryst Pharmaceuticals' Short Interest. When is BioCryst Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our BCRX earnings forecast. How were BioCryst Pharmaceuticals' earnings last quarter? BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced its earnings results on Monday, May, 6th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.06. The biotechnology company earned $92.80 million during the quarter, compared to analyst estimates of $85.62 million. The firm's quarterly revenue was up 34.9% on a year-over-year basis. During the same period in the previous year, the company earned ($0.28) EPS. What ETFs hold BioCryst Pharmaceuticals' stock? ETFs with the largest weight of BioCryst Pharmaceuticals (NASDAQ:BCRX) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM) and Virtus LifeSci Biotech Products ETF (BBP).iShares Genomics Immunology and Healthcare ETF (IDNA). What is Jon P. Stonehouse's approval rating as BioCryst Pharmaceuticals' CEO? 9 employees have rated BioCryst Pharmaceuticals Chief Executive Officer Jon P. Stonehouse on Glassdoor.com. Jon P. Stonehouse has an approval rating of 40% among the company's employees. This puts Jon P. Stonehouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 64.0% of employees surveyed would recommend working at BioCryst Pharmaceuticals to a friend. What other stocks do shareholders of BioCryst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioCryst Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), El Pollo Loco (LOCO), Advanced Micro Devices (AMD), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Dynavax Technologies (DVAX), La Jolla Pharmaceutical (LJPC), Novavax (NVAX), Sorrento Therapeutics (SRNE) and VBI Vaccines (VBIV). Who are BioCryst Pharmaceuticals' major shareholders? BioCryst Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Rice Hall James & Associates LLC (1.04%), Assenagon Asset Management S.A. (0.19%), Swiss National Bank (0.18%), Mutual of America Capital Management LLC (0.10%), BNP Paribas Financial Markets (0.08%) and Mirae Asset Global Investments Co. Ltd. (0.07%). Insiders that own company stock include Alane P Barnes, Anthony Doyle, George B Abercrombie, George B Abercrombie, Helen M Thackray, Jon P Stonehouse, Machelle Sanders, Michael L Jones, Nancy J Hutson, Vincent Milano, William P Sheridan and Yarlagadda S Babu. View institutional ownership trends. How do I buy shares of BioCryst Pharmaceuticals? Shares of BCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BCRX) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyElon Musk Secret Crypto Plot ExposedCrypto 101 MediaAI “wealth window” is closing June 25thParadigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
